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Perspectives
In ophthalmology, the designation of 
trachoma, onchocerciasis and leprosy 
as neglected tropical diseases (NTDs) 
has sustained efforts to combat these 
blinding conditions worldwide. Over 
the past 50 years, NTD designations 
have enabled the joining of political, 
social and economic forces to promote 
research and interventions for diseases 
that overwhelmingly affect the 3 bil-
lion people who subsist on less than 
2 United States dollars (US$) a day.1 The 
global public health landscape is still 
dominated by focus on human immu-
nodeficiency virus (HIV), tuberculosis 
and malaria. However, NTDs are now 
increasingly recognized as important 
causes of morbidity and mortality in 
low-income settings, perpetuating 
stigma and social isolation, with many 
NTDs leading to disfiguring complica-
tions. In international public health 
diplomacy, formal disease recognition is 
essential. The pursuit of this recognition 
drives proposals from World Health Or-
ganization’s (WHO’s) Member States to 
include additional diseases in the list of 
NTDs. The intention is to strengthen the 
development of partnerships, epidemio-
logical frameworks and commitment of 
resources to achieve the aims set by the 
sustainable development goals.2
Despite ongoing efforts to end pre-
ventable blindness, infectious corneal 
ulceration still receives insufficient at-
tention for reasons that are unclear. The 
condition occurs when microbes from 
the environment invade the cornea to 
produce inflammation which in turn 
leads to ulceration. A study conducted 
two decades ago estimated that over 
1.5 million people worldwide will devel-
op blindness from infectious corneal ul-
ceration each year,3 a number that most 
likely underrepresents the true scale 
of this disease. Our combined clinical 
experience suggests that an even greater 
number will experience visual disability, 
mostly unilateral, that will fall just short 
of current WHO-defined measures of 
blindness. Nonetheless, infectious cor-
neal ulcers are the most common cause 
of non-trachomatous corneal opacifica-
tion, and the fifth leading cause of blind-
ness overall, responsible for up to 3.5% 
(36 million) of all blind persons as of 
2015.4 Most of this burden falls on low-
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income countries, where the etiology, 
epidemiology and patterns of clinical 
presentation are distinct from those in 
high-income countries, and where it is 
not uncommon for loss of vision in one 
eye to portend future loss in the other. 
Children who are affected by infec-
tious corneal ulceration face a lifetime 
of increased general morbidity, with the 
onset of visual impairment also strongly 
associated with increased risk of child-
hood mortality.5 With the burden of cor-
neal ulceration in low-income countries 
now surpassing the traditional blinding 
diseases in magnitude,6 the inclusion of 
infectious corneal ulcers among cur-
rently recognized NTDs could be the 
first step in addressing the needs of 
those affected. Should this inclusion not 
happen, re-examining infectious corneal 
ulceration through the NTD paradigm 
may nonetheless inspire the necessary 
collective discussion and action as we 
move beyond the global initiative VI-
SION 2020.5
Viewing infectious corneal ulcers as 
an NTD can help us analyse how we can 
apply elements of historically successful 
public health campaigns in ophthalmol-
ogy to this disease. The successes of the 
SAFE (surgery, antibiotics, cleanliness 
and environmental change) strategy for 
trachoma, as well as the administration 
of yearly or biannual ivermectin for on-
chocerciasis, remain driven primarily by 
the robust partnerships created between 
local community health centres in un-
derserved areas, government agencies, 
nongovernmental organizations and 
pharmaceutical companies. Between 
1990 and 2013, these programmes 
contributed to dramatic declines in 
the global prevalence of trachoma and 
onchocerciasis.7
Infectious corneal ulceration dis-
proportionately affects farming-based 
societies across the WHO Regions of 
Africa, the Americas, South-East Asia 
and Western Pacific. Agricultural work-
ers are at increased risk for minor ocular 
trauma, which in turn can lead to infec-
tion with pathogens ubiquitous in soil, 
plant matter and water. Without prompt 
medical attention, even a minor corneal 
abrasion can develop into a blinding 
corneal ulcer. The severity of infectious 
corneal ulceration is also worsened by 
vitamin A deficiency, commonly the 
result of poor nutritional status, and 
independently associated with corneal 
ulceration and blindness. Additionally, 
the emergence of antimicrobial resis-
tance and the harmful use of widely 
available traditional eye medicines8 and 
topical corticosteroids all may lead to 
poorer disease outcomes. Considering 
the social, economic, environmental, 
and cultural risk factors for infectious 
corneal ulceration and the number of 
individuals living in high-risk areas, we 
should not expect the incidence of this 
disease to decrease without population-
based interventions.
One solution to the problem of 
infectious corneal ulceration may lie 
in the delivery of a simple, safe and 
effective community-based strategy. 
NTDs are considered preventable and 
treatable. The main etiologies of infec-
tious corneal ulcers, including bacteria, 
fungi and parasites, are often clinically 
indistinguishable and any attempt to 
reduce their burden must take the broad 
range of causative organisms into con-
sideration. 
Past attempts to reduce the bur-
den of infectious corneal ulcers have 
involved community health promotion 
campaigns and the mobilization of 
trained community eye workers to reach 
remote or rural areas. In 2018, study 
subject recruitment was completed for 
the Village-Integrated Eye Worker trial, 
a cluster-randomized study in Nepal that 
aims to evaluate the effectiveness of 1% 
chloramphenicol and 1% itraconazole 
ointment to prevent corneal abrasions 
from becoming corneal ulcers.9 Con-
ducted on the precedent of similar, but 
non-randomized studies in India and 
Nepal,10,11 the trial may perhaps provide 
the necessary efficacy, cost and feasibil-
ity data, and therefore the scientific and 
clinical grounds, for what is a simple 
intervention. 
An important distinction between 
the aforementioned trial and other pub-
lic health campaigns, such as the SAFE 
(surgery, antibiotics, facial cleanliness 
and environmental change) strategy is 
that the former is an example of primary 
prevention and seeks to counteract the 
onset of the condition. Clearly, the pos-
sibility of establishing cost–effective, 
community-driven models of eyecare 
exists, wherein pharmacological pro-
phylaxis is augmented by educational 
initiatives and distribution of protective 
eyewear. The Village-Integrated Eye 
Worker trial may provide an insight into 
how ophthalmologists, eye health-care 
workers and public health practitioners 
collaborate to prevent infectious corneal 
ulceration in low-income countries.
Beyond the prospect of mobilizing 
the necessary resources that may come 
with NTD recognition, rethinking infec-
tious corneal ulceration in this manner 
may improve our current poor under-
standing of its global epidemiology. 
For infectious corneal ulcers, even the 
most basic data, incidence, prevalence, 
contribution to disability-adjusted life 
years, and loss of productivity indices, 
all remain unknown. The only data 
available comes from outdated popula-
tion surveys, which suggest that South 
and South-East Asia are the epicentres of 
disease, with reported incidences of 113 
per 100 000 persons in India,12 339 per 
100 000 in Bhutan,8 710 per 100 000 in 
Burma8 and 799 per 100 000 in Nepal.11 
Mapping of key endemic areas and 
establishment of disease surveillance 
systems are needed, particularly in areas 
where no such data exists. Furthermore, 
the historical inclusion of infectious 
corneal ulcers as a major cause of cor-
neal opacity has not provided the detail 
required for accurate epidemiological 
study. Separating infectious corneal 
ulcers from these blanket descriptions 
may provide the necessary information 
to generate interest among global and 
regional health agencies. 
Innovations in corneal ulcer care 
worldwide may include improvements 
in the treatment of frequently recalci-
trant fungal ulcers that predominate 
in low-income countries, as well as the 
selection of antimicrobials according 
to regional pathogen distributions and 
the development of novel therapeutic 
agents to minimize corneal scarring 
of sufficient severity to impact vision. 
Strategies to reduce the burden of infec-
tious corneal ulceration will also involve 
tailoring sustainable public health 
interventions according to the specific 
needs of communities where such care 
is needed most.
To eliminate avoidable blindness, 
we must address the burden of infec-
tious corneal ulcers. With the results 
from trials such as Village-Integrated 
Eye Worker trial pending, we may 
soon have evidence of a practical and 
replicable demonstration of the value 
of corneal ulcer prophylaxis within 
resource-constrained settings. The 
relatively scarce attention given to 
infectious corneal ulceration does not 
reflect the impact of the condition on the 
most vulnerable, many of whom live in 
poverty. The classification of infectious 
corneal ulceration as an NTD would be 
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timely and appropriate and would allow 
us to adequately address this relatively 
overlooked disease. ■
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